FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W4213277489> ?p ?o ?g. }

• W4213277489 abstract "Future Medicinal ChemistryVol. 14, No. 7 EditorialTargeting TGF-β: triumphs and challengesBaku Acharya, Sayem Miah & Brendan FrettBaku AcharyaDepartment of Pharmaceutical Sciences, College of Pharmacy, University of Arkansas for Medical Sciences, Little Rock, AR 72205, USASearch for more papers by this author, Sayem MiahDepartment of Biochemistry & Molecular Biology, College of Medicine, University of Arkansas for Medical Sciences, Little Rock, AR 72205, USASearch for more papers by this author & Brendan Frett *Author for correspondence: E-mail Address: BAFrett@uams.eduhttps://orcid.org/0000-0003-2429-8895Department of Pharmaceutical Sciences, College of Pharmacy, University of Arkansas for Medical Sciences, Little Rock, AR 72205, USASearch for more papers by this authorPublished Online:13 Feb 2022https://doi.org/10.4155/fmc-2021-0344AboutSectionsView ArticleView Full TextPDF/EPUB ToolsAdd to favoritesDownload CitationsTrack CitationsPermissionsReprints ShareShare onFacebookTwitterLinkedInReddit View articleKeywords: clinical translationimmunoncologyoncologypleiotropytemporalTGF-βtumor microenvironmentReferences1. Tzavlaki K, Moustakas A. TGF-β signaling. Biomolecules 10(3), 487 (2020).Crossref, CAS, Google Scholar2. Smith AL, Robin TP, Ford HL. Molecular pathways: targeting the TGF-β pathway for cancer therapy. Clin. Cancer Res. 18(17), 4514 (2012).Crossref, Medline, CAS, Google Scholar3. Teicher BA. TGFβ-directed therapeutics: 2020. Pharmacol. Ther. 217, 107666 (2021).Crossref, Medline, CAS, Google Scholar4. Huang C-Y, Chung C-L, Hu T-H, Chen J-J, Liu P-F, Chen C-L. Recent progress in TGF-β inhibitors for cancer therapy. Biomed. Pharmacother. 134, 111046 (2021).Crossref, Medline, CAS, Google Scholar5. Morris JC, Tan AR, Olencki TE et al. Phase I study of GC1008 (fresolimumab): a human anti-transforming growth factor-beta (TGFβ) monoclonal antibody in patients with advanced malignant melanoma or renal cell carcinoma. PLoS ONE 9(3), e90353 (2014).Crossref, Medline, Google Scholar6. Tolcher AW, Berlin JD, Cosaert J et al. A phase 1 study of anti-TGFβ receptor type-II monoclonal antibody LY3022859 in patients with advanced solid tumors. Cancer Chemother. Pharmacol. 79(4), 673–680 (2017).Crossref, Medline, CAS, Google Scholar7. Yap TA, Lakhani NJ, Araujo DV et al. AVID200, First-in-class TGF-beta 1 and 3 selective and potent inhibitor: safety and biomarker results of a phase I monotherapy dose-escalation study in patients with advanced solid tumors. J. Clin. Oncol. 38(Suppl. 15), 3587–3587 (2020).Crossref, Medline, Google Scholar8. Kim B-G, Malek E, Choi SH, Ignatz-Hoover JJ, Driscoll JJ. Novel therapies emerging in oncology to target the TGF-β pathway. J. Hematol. Oncol. 14(1), 55 (2021).Crossref, Medline, CAS, Google Scholar9. Schlingensiepen K-H, Schlingensiepen R, Steinbrecher A et al. Targeted tumor therapy with the TGF-β2 antisense compound AP 12009. Cytokine Growth Factor Rev. 17(1), 129–139 (2006).Crossref, Medline, CAS, Google Scholar10. Hau P, Kunst M, Pichler J et al. Targeted downregulation of TGF-beta2 as immunotherapy for high-grade glioma: a phase IIb study. J. Clin. Oncol. 23(Suppl. 16), 1537–1537 (2005).Crossref, Google Scholar11. Jung SY, Hwang S, Clarke JM et al. Pharmacokinetic characteristics of vactosertib, a new activin receptor-like kinase 5 inhibitor, in patients with advanced solid tumors in a first-in-human phase 1 study. Invest. New Drugs 38(3), 812–820 (2020).Crossref, Medline, CAS, Google Scholar12. Jung SY, Yug JS, Clarke JM et al. Population pharmacokinetics of vactosertib, a new TGF-β receptor type I inhibitor, in patients with advanced solid tumors. Cancer Chemother. Pharmacol. 85(1), 173–183 (2020).Crossref, Medline, CAS, Google Scholar13. Thomas DA, Massagué J. TGF-β directly targets cytotoxic T cell functions during tumor evasion of immune surveillance. Cancer Cell 8(5), 369–380 (2005).Crossref, Medline, CAS, Google Scholar14. Schiavinato JLDS, Haddad R, Saldanha-Araujo F et al. TGF-beta/atRA-induced Tregs express a selected set of microRNAs involved in the repression of transcripts related to Th17 differentiation. Sci. Rep. 7(1), 3627 (2017).Crossref, Medline, Google Scholar15. Dodagatta-Marri E, Meyer DS, Reeves MQ et al. α-PD-1 Therapy elevates Treg/Th balance and increases tumor cell pSmad3 that are both targeted by α-TGFβ antibody to promote durable rejection and immunity in squamous cell carcinomas. J. Immunother. Cancer 7(1), 62 (2019).Crossref, Medline, CAS, Google Scholar16. Sow HS, Ren J, Camps M, Ossendorp F, Ten Dijke P. Combined inhibition of TGF-β signaling and the PD-L1 immune checkpoint is differentially effective in tumor models. Cells 8(4), 320 (2019).Crossref, CAS, Google Scholar17. Huynh LK, Hipolito CJ, Ten Dijke P. A perspective on the development of TGF-β inhibitors for cancer treatment. Biomolecules 9(11), 743 (2019).Crossref, CAS, Google Scholar18. Colak S, Ten Dijke P. Targeting TGF-β signaling in cancer. Trends Cancer 3(1), 56–71 (2017).Crossref, Medline, CAS, Google Scholar19. Biswas T, Gu X, Yang J, Ellies LG, Sun L-Z. Attenuation of TGF-β signaling supports tumor progression of a mesenchymal-like mammary tumor cell line in a syngeneic murine model. Cancer Lett. 346(1), 129–138 (2014).Crossref, Medline, CAS, Google Scholar20. Teixeira AF, Ten Dijke P, Zhu H-J. On-target anti-TGF-β therapies are not succeeding in clinical cancer treatments: what are remaining challenges? Front. Cell Dev. Biol. 8, 605 (2020).Crossref, Medline, Google ScholarFiguresReferencesRelatedDetails Vol. 14, No. 7 Follow us on social media for the latest updates Metrics Downloaded 73 times History Received 14 December 2021 Accepted 26 January 2022 Published online 13 February 2022 Published in print April 2022 Information© 2022 Newlands PressKeywordsclinical translationimmunoncologyoncologypleiotropytemporalTGF-βtumor microenvironmentFinancial & competing interests disclosureThis work was supported by the National Institutes of General Medical Sciences (P20GM109005) and startup funds provided by the UAMS Winthrop P Rockefeller Cancer Institute. The authors have no other relevant affiliations or financial involvement with any organization or entity with a financial interest in or financial conflict with the subject matter or materials discussed in the manuscript apart from those disclosed.No writing assistance was utilized in the production of this manuscript.PDF download" @default.
• W4213277489 created "2022-02-24" @default.
• W4213277489 creator A5024846231 @default.
• W4213277489 creator A5039675686 @default.
• W4213277489 creator A5086385428 @default.
• W4213277489 date "2022-02-13" @default.
• W4213277489 modified "2023-10-02" @default.
• W4213277489 title "Targeting TGF-β: triumphs and challenges" @default.
• W4213277489 cites W2011243140 @default.
• W4213277489 cites W2074604431 @default.
• W4213277489 cites W2075873658 @default.
• W4213277489 cites W2099541675 @default.
• W4213277489 cites W2148925386 @default.
• W4213277489 cites W2570763587 @default.
• W4213277489 cites W2593598026 @default.
• W4213277489 cites W2621975546 @default.
• W4213277489 cites W2922510644 @default.
• W4213277489 cites W2931391344 @default.
• W4213277489 cites W2958406986 @default.
• W4213277489 cites W2987225757 @default.
• W4213277489 cites W2989285795 @default.
• W4213277489 cites W3012775092 @default.
• W4213277489 cites W3032848507 @default.
• W4213277489 cites W3040737854 @default.
• W4213277489 cites W3080672636 @default.
• W4213277489 cites W3112064419 @default.
• W4213277489 cites W3149714833 @default.
• W4213277489 cites W97383484 @default.
• W4213277489 doi "https://doi.org/10.4155/fmc-2021-0344" @default.
• W4213277489 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/35152715" @default.
• W4213277489 hasPublicationYear "2022" @default.
• W4213277489 type Work @default.
• W4213277489 citedByCount "1" @default.
• W4213277489 countsByYear W42132774892023 @default.
• W4213277489 crossrefType "journal-article" @default.
• W4213277489 hasAuthorship W4213277489A5024846231 @default.
• W4213277489 hasAuthorship W4213277489A5039675686 @default.
• W4213277489 hasAuthorship W4213277489A5086385428 @default.
• W4213277489 hasConcept C104863432 @default.
• W4213277489 hasConcept C143998085 @default.
• W4213277489 hasConcept C161191863 @default.
• W4213277489 hasConcept C185592680 @default.
• W4213277489 hasConcept C2779473830 @default.
• W4213277489 hasConcept C41008148 @default.
• W4213277489 hasConcept C502942594 @default.
• W4213277489 hasConcept C512399662 @default.
• W4213277489 hasConcept C55493867 @default.
• W4213277489 hasConcept C71924100 @default.
• W4213277489 hasConceptScore W4213277489C104863432 @default.
• W4213277489 hasConceptScore W4213277489C143998085 @default.
• W4213277489 hasConceptScore W4213277489C161191863 @default.
• W4213277489 hasConceptScore W4213277489C185592680 @default.
• W4213277489 hasConceptScore W4213277489C2779473830 @default.
• W4213277489 hasConceptScore W4213277489C41008148 @default.
• W4213277489 hasConceptScore W4213277489C502942594 @default.
• W4213277489 hasConceptScore W4213277489C512399662 @default.
• W4213277489 hasConceptScore W4213277489C55493867 @default.
• W4213277489 hasConceptScore W4213277489C71924100 @default.
• W4213277489 hasFunder F4320337354 @default.
• W4213277489 hasLocation W42132774891 @default.
• W4213277489 hasLocation W42132774892 @default.
• W4213277489 hasOpenAccess W4213277489 @default.
• W4213277489 hasPrimaryLocation W42132774891 @default.
• W4213277489 hasRelatedWork W135528526 @default.
• W4213277489 hasRelatedWork W1546820302 @default.
• W4213277489 hasRelatedWork W1923367337 @default.
• W4213277489 hasRelatedWork W1995515455 @default.
• W4213277489 hasRelatedWork W2039318446 @default.
• W4213277489 hasRelatedWork W2080531066 @default.
• W4213277489 hasRelatedWork W2748952813 @default.
• W4213277489 hasRelatedWork W2899084033 @default.
• W4213277489 hasRelatedWork W2969083999 @default.
• W4213277489 hasRelatedWork W3032375762 @default.
• W4213277489 isParatext "false" @default.
• W4213277489 isRetracted "false" @default.
• W4213277489 workType "article" @default.